RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Fernando Villalta to Trypanosoma cruzi

This is a "connection" page, showing publications Fernando Villalta has written about Trypanosoma cruzi.
Connection Strength

5.254
  1. Johnson CA, Rachakonda G, Kleshchenko YY, Nde PN, Madison MN, Pratap S, Cardenas TC, Taylor C, Lima MF, Villalta F. Cellular response to Trypanosoma cruzi infection induces secretion of defensin a-1, which damages the flagellum, neutralizes trypanosome motility, and inhibits infection. Infect Immun. 2013 Nov; 81(11):4139-48.
    View in: PubMed
    Score: 0.420
  2. Kleschenko YE, Karpenko LP, Villalta F. Effects of human defensin-a(1)on Trypanosoma cruzi trypomastigotes in vitro. Bull Exp Biol Med. 2010 Nov; 149(6):731-3.
    View in: PubMed
    Score: 0.346
  3. Nde PN, Johnson CA, Pratap S, Cardenas TC, Kleshchenko YY, Furtak VA, Simmons KJ, Lima MF, Villalta F. Gene network analysis during early infection of human coronary artery smooth muscle cells by Trypanosoma cruzi and Its gp83 ligand. Chem Biodivers. 2010 May; 7(5):1051-64.
    View in: PubMed
    Score: 0.334
  4. Villalta F, Scharfstein J, Ashton AW, Tyler KM, Guan F, Mukherjee S, Lima MF, Alvarez S, Weiss LM, Huang H, Machado FS, Tanowitz HB. Perspectives on the Trypanosoma cruzi-host cell receptor interactions. Parasitol Res. 2009 Jun; 104(6):1251-60.
    View in: PubMed
    Score: 0.309
  5. Villalta F, Madison MN, Kleshchenko YY, Nde PN, Lima MF. Molecular analysis of early host cell infection by Trypanosoma cruzi. Front Biosci. 2008 May 01; 13:3714-34.
    View in: PubMed
    Score: 0.291
  6. Madison MN, Kleshchenko YY, Nde PN, Simmons KJ, Lima MF, Villalta F. Human defensin alpha-1 causes Trypanosoma cruzi membrane pore formation and induces DNA fragmentation, which leads to trypanosome destruction. Infect Immun. 2007 Oct; 75(10):4780-91.
    View in: PubMed
    Score: 0.275
  7. Augustine SA, Kleshchenko YY, Nde PN, Pratap S, Ager EA, Burns JM, Lima MF, Villalta F. Molecular cloning of a Trypanosoma cruzi cell surface casein kinase II substrate, Tc-1, involved in cellular infection. Infect Immun. 2006 Jul; 74(7):3922-9.
    View in: PubMed
    Score: 0.256
  8. Simmons KJ, Nde PN, Kleshchenko YY, Lima MF, Villalta F. Stable RNA interference of host thrombospondin-1 blocks Trypanosoma cruzi infection. FEBS Lett. 2006 Apr 17; 580(9):2365-70.
    View in: PubMed
    Score: 0.252
  9. Nde PN, Simmons KJ, Kleshchenko YY, Pratap S, Lima MF, Villalta F. Silencing of the laminin gamma-1 gene blocks Trypanosoma cruzi infection. Infect Immun. 2006 Mar; 74(3):1643-8.
    View in: PubMed
    Score: 0.250
  10. Kleshchenko YY, Moody TN, Furtak VA, Ochieng J, Lima MF, Villalta F. Human galectin-3 promotes Trypanosoma cruzi adhesion to human coronary artery smooth muscle cells. Infect Immun. 2004 Nov; 72(11):6717-21.
    View in: PubMed
    Score: 0.228
  11. Rayford KJ, Cooley A, Arun A, Rachakonda G, Kleschenko Y, Villalta F, Pratap S, Lima MF, Nde PN. Trypanosoma cruzi Modulates PIWI-Interacting RNA Expression in Primary Human Cardiac Myocytes during the Early Phase of Infection. Int J Mol Sci. 2020 Dec 11; 21(24).
    View in: PubMed
    Score: 0.174
  12. Arun A, Rayford KJ, Cooley A, Rachakonda G, Villalta F, Pratap S, Lima MF, Sheibani N, Nde PN. Thrombospondin-1 Plays an Essential Role in Yes-Associated Protein Nuclear Translocation during the Early Phase of Trypanosoma cruzi Infection in Heart Endothelial Cells. Int J Mol Sci. 2020 Jul 12; 21(14).
    View in: PubMed
    Score: 0.169
  13. Moody TN, Ochieng J, Villalta F. Novel mechanism that Trypanosoma cruzi uses to adhere to the extracellular matrix mediated by human galectin-3. FEBS Lett. 2000 Mar 31; 470(3):305-8.
    View in: PubMed
    Score: 0.166
  14. Guedes-da-Silva FH, Batista DDGJ, Da Silva CF, Pav?o BP, Batista MM, Moreira OC, Souza LRQ, Britto C, Rachakonda G, Villalta F, Lepesheva GI, Soeiro MNC. Successful Aspects of the Coadministration of Sterol 14a-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi. ACS Infect Dis. 2019 03 08; 5(3):365-371.
    View in: PubMed
    Score: 0.153
  15. Friggeri L, Hargrove TY, Rachakonda G, Blobaum AL, Fisher P, de Oliveira GM, da Silva CF, Soeiro MNC, Nes WD, Lindsley CW, Villalta F, Guengerich FP, Lepesheva GI. Sterol 14a-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae. J Med Chem. 2018 12 13; 61(23):10910-10921.
    View in: PubMed
    Score: 0.151
  16. Suman S, Rachakonda G, Mandape SN, Sakhare SS, Villalta F, Pratap S, Lima MF, Nde PN. Phospho-proteomic analysis of primary human colon epithelial cells during the early Trypanosoma cruzi infection phase. PLoS Negl Trop Dis. 2018 09; 12(9):e0006792.
    View in: PubMed
    Score: 0.149
  17. Udoko AN, Johnson CA, Dykan A, Rachakonda G, Villalta F, Mandape SN, Lima MF, Pratap S, Nde PN. Early Regulation of Profibrotic Genes in Primary Human Cardiac Myocytes by Trypanosoma cruzi. PLoS Negl Trop Dis. 2016 Jan; 10(1):e0003747.
    View in: PubMed
    Score: 0.124
  18. Hoekstra WJ, Hargrove TY, Wawrzak Z, da Gama Jaen Batista D, da Silva CF, Nefertiti AS, Rachakonda G, Schotzinger RJ, Villalta F, Soeiro Mde N, Lepesheva GI. Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi. Antimicrob Agents Chemother. 2016 Feb; 60(2):1058-66.
    View in: PubMed
    Score: 0.123
  19. Lepesheva GI, Hargrove TY, Rachakonda G, Wawrzak Z, Pomel S, Cojean S, Nde PN, Nes WD, Locuson CW, Calcutt MW, Waterman MR, Daniels JS, Loiseau PM, Villalta F. VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis. J Infect Dis. 2015 Nov 01; 212(9):1439-48.
    View in: PubMed
    Score: 0.118
  20. Farrow AL, Rachakonda G, Gu L, Krendelchtchikova V, Nde PN, Pratap S, Lima MF, Villalta F, Matthews QL. Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2014 Aug; 8(8):e3089.
    View in: PubMed
    Score: 0.113
  21. Friggeri L, Hargrove TY, Rachakonda G, Williams AD, Wawrzak Z, Di Santo R, De Vita D, Waterman MR, Tortorella S, Villalta F, Lepesheva GI. Structural basis for rational design of inhibitors targeting Trypanosoma cruzi sterol 14a-demethylase: two regions of the enzyme molecule potentiate its inhibition. J Med Chem. 2014 Aug 14; 57(15):6704-17.
    View in: PubMed
    Score: 0.112
  22. Dobish MC, Villalta F, Waterman MR, Lepesheva GI, Johnston JN. Organocatalytic, enantioselective synthesis of VNI: a robust therapeutic development platform for Chagas, a neglected tropical disease. Org Lett. 2012 Dec 21; 14(24):6322-5.
    View in: PubMed
    Score: 0.100
  23. Johnson CA, Kleshchenko YY, Ikejiani AO, Udoko AN, Cardenas TC, Pratap S, Duquette MA, Lima MF, Lawler J, Villalta F, Nde PN. Thrombospondin-1 interacts with Trypanosoma cruzi surface calreticulin to enhance cellular infection. PLoS One. 2012; 7(7):e40614.
    View in: PubMed
    Score: 0.097
  24. Lepesheva GI, Villalta F, Waterman MR. Targeting Trypanosoma cruzi sterol 14a-demethylase (CYP51). Adv Parasitol. 2011; 75:65-87.
    View in: PubMed
    Score: 0.087
  25. Lepesheva GI, Hargrove TY, Anderson S, Kleshchenko Y, Furtak V, Wawrzak Z, Villalta F, Waterman MR. Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi. J Biol Chem. 2010 Aug 13; 285(33):25582-90.
    View in: PubMed
    Score: 0.084
  26. Konkle ME, Hargrove TY, Kleshchenko YY, von Kries JP, Ridenour W, Uddin MJ, Caprioli RM, Marnett LJ, Nes WD, Villalta F, Waterman MR, Lepesheva GI. Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase. J Med Chem. 2009 May 14; 52(9):2846-53.
    View in: PubMed
    Score: 0.078
  27. Noisin EL, Villalta F. Fibronectin increases Trypanosoma cruzi amastigote binding to and uptake by murine macrophages and human monocytes. Infect Immun. 1989 Apr; 57(4):1030-4.
    View in: PubMed
    Score: 0.077
  28. Lepesheva GI, Ott RD, Hargrove TY, Kleshchenko YY, Schuster I, Nes WD, Hill GC, Villalta F, Waterman MR. Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. Chem Biol. 2007 Nov; 14(11):1283-93.
    View in: PubMed
    Score: 0.070
  29. Alexander AD, Villalta F, Lima MF. Transforming growth factor alpha binds to Trypanosoma cruzi amastigotes to induce signaling and cellular proliferation. Infect Immun. 2003 Jul; 71(7):4201-5.
    View in: PubMed
    Score: 0.052
  30. Turner CW, Lima MF, Villalta F. Trypanosoma cruzi uses a 45-kDa mucin for adhesion to mammalian cells. Biochem Biophys Res Commun. 2002 Jan 11; 290(1):29-34.
    View in: PubMed
    Score: 0.047
  31. Arun A, Rayford KJ, Cooley A, Rana T, Rachakonda G, Villalta F, Pratap S, Lima MF, Sheibani N, Nde PN. Thrombospondin-1 expression and modulation of Wnt and hippo signaling pathways during the early phase of Trypanosoma cruzi infection of heart endothelial cells. PLoS Negl Trop Dis. 2022 01; 16(1):e0010074.
    View in: PubMed
    Score: 0.047
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support